drugset / Trial / NCT05290090
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
NaSingle-groupOpen-labelTreatment
Summary
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy. The poor prognosis of elderly DLBCL patients may be related to the biological behavior of the disease, more comorbidities, poor performance status, and inability to tolerate standard-intensity immunochemotherapy. The investigators plan to use ZR2 regimen(rituximab, lenalidomide and zanubrutinib) for 2 cycles followed by immunochemotherapy for up to 4 cycles in elderly newly diagnosed DLBCL patients.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2024-06-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 35 mg/m2 | — |
| Background | Epirubicin | Small molecule | 75 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 100 mg | — |
| Background | Vindesine | Small molecule | 4 mg | — |